Equillium (FRA:0FY) Other Gross PPE : €0.69 Mil (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Equillium Other Gross PPE?

Equillium's Other Gross PPE for the quarter that ended in Sep. 2024 was €0.69 Mil.

Equillium's quarterly Other Gross PPE declined from Mar. 2024 (€0.97 Mil) to Jun. 2024 (€0.86 Mil) and declined from Jun. 2024 (€0.86 Mil) to Sep. 2024 (€0.69 Mil).

Equillium's annual Other Gross PPE declined from Dec. 2021 (€1.46 Mil) to Dec. 2022 (€1.14 Mil) and declined from Dec. 2022 (€1.14 Mil) to Dec. 2023 (€0.75 Mil).

Equillium Other Gross PPE Historical Data

The historical data trend for Equillium's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Equillium Other Gross PPE Chart

Equillium Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Gross PPE

Get a 7-Day Free Trial

1.46

1.14

0.75

Equillium Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Gross PPE	Get a 7-Day Free Trial															1.16	0.75	0.97	0.86	0.69

Equillium Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Equillium Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (FRA:0FY) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

EQ:USA 0A4D:UK 0FY:Germany

Address

2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037

Website

https://www.equilliumbio.com

Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Equillium Headlines

No Headlines